ArticleFrontiers in oncology2025
Patterns of care in pancreatic cancer radiotherapy: impact of facility volume on outcomes.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Objectives: Radiotherapy (RT), particularly stereotactic body radiotherapy (SBRT), is a promising treatment for borderline resectable or locally advanced pancreatic cancer (PC). This study evaluated the association of RT facility volume with overall survival (OS) and examined patterns of care for patients with PC. Methods: A retrospective cohort study using National Cancer Database (NCDB) data (2004-2019) included 17,053 PC patients treated with RT, excluding those with metastatic or stage IV disease. RT facility volumes were categorized as low- (<10 cases/year), intermediate- (10-20 cases/year), and high-volume (>20 cases/year). Predictors of OS, including facility volume, RT type, and patient/treatment factors, were evaluated. Results: Among 17,053 patients (median age 67 years, 51.4% male), 17.6% received SBRT, and 27.1% were treated at high-volume centers. Treatment at high-volume centers (HR 0.863, p<0.001) and receiving SBRT (HR 0.869, p<0.001) were associated with improved OS. SBRT use increased from 8.5% (2004-2011) to 30% (2016-2019). Conclusion: High-volume RT centers are associated with significantly better survival outcomes in PC patients, particularly those receiving SBRT. These findings emphasize the need to expand access to high-volume centers and develop standardized treatment protocols to improve care and outcomes for all patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.